ADVENTRX Pharmaceuticals to Present at Biotechnology Industry Organization Annual Meeting
May 02 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) today announced today that Brian
M. Culley, ADVENTRX's chief business officer and senior vice
president, will present a company overview at the upcoming
Biotechnology Industry Organization (BIO) Annual Meeting in Boston.
Mr. Culley is scheduled to present on Tuesday, May 8 at 9:30 a.m.
Eastern Time. The conference takes place May 6-9, 2007. About
ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems, such as drug metabolism and bioavailability,
excessive toxicity and treatment resistance. The Company's lead
product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b
clinical trials for the treatment of metastatic colorectal cancer,
as well as in a Phase 2 clinical trial for the treatment of
advanced breast cancer. More information can be found on ADVENTRX's
web site at http://www.adventrx.com/. Forward Looking Statement
ADVENTRX cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements that involve risks and assumptions that,
if they materialize or do not prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or
those expressed or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to:
uncertainties inherent in the drug development process; the timing
and success of clinical trials; the validity of research results;
the receipt of necessary approvals from the FDA and other
regulatory agencies; and other risks and uncertainties more fully
described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with
the Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866; or Media, Edie DeVine of WeissComm Partners,
+1-415-946-1081, for ADVENTRX Pharmaceuticals Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024